Suchergebnisse - "Horn, Heike"

PubPharm (8)

1

Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma : 10-year follow-up of a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Haematology | 2021

von Frontzek, F. | Ziepert, M. | Nickelsen, M. | +18

CommentIn: Lancet Haematol. 2021 Apr;8(4):e242-e243. - PMID 33667421

2

Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models

enthalten in: Blood advances | 2020

von Alig, S. | Jurinovic, V. | Shahrokh Esfahani, M. | +23

3

FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy

enthalten in: Blood | 2018

von Mottok, A. | Jurinovic, V. | Farinha, P. | +14

4

TP53 mutation and survival in aggressive B cell lymphoma

enthalten in: International journal of cancer | 2017

von Zenz, T. | Kreuz, M. | Fuge, M. | +19

5

Clinical Impact of the Cell-of-Origin Classification and the MYC/ BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2017

von Staiger, A. | Ziepert, M. | Horn, H. | +21

6

Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma : a retrospective analysis of a prospective clinical trial and validation in a population-based registry

enthalten in: The Lancet. Oncology | 2015

von Pastore, A. | Jurinovic, V. | Kridel, R. | +32

CommentIn: Lancet Oncol. 2015 Sep;16(9):1011-2. - PMID 26256759

7

MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

enthalten in: Blood | 2013

von Horn, H. | Ziepert, M. | Becher, C. | +18

CommentIn: Blood. 2013 Mar 21;121(12):2165-6. - PMID 23520325

8

Immunoblastic morphology but not the immunohistochemical GCB/nonGCB classifier predicts outcome in diffuse large B-cell lymphoma in the RICOVER-60 trial of the DSHNHL

enthalten in: Blood | 2010

von Ott, G. | Ziepert, M. | Klapper, W. | +19

1
[1]